The Ledger
Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.
why aren't all 15 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable
Eli Lilly claimed rebates account for 75% of insulin's sticker price
“Eli Lilly has publicly claimed that the cost of these discounts and rebates accounted for 75% of the sticker price of insulin.”
Novo Nordisk's 84% gross margins surpass Microsoft and Google
“Gross margins are better than software. They run about 84%. Lilly is also a very high margin company, running about 80%. For context, Microsoft has a gross margin of 70% and Google is 56%.”
Novo Nordisk derives 85% of revenue from metabolic disorders
“85% of their revenue is dedicated to metabolic disorders.
They are the second largest market cap pharma, second only to Eli Lilly.”
Clinical studies show Mounjaro produces more weight loss than Ozempic
“The studies show Manjaro helps you lose more weight and has a very similar mechanism plus another mechanism that together work, but like, most people don't know that.”
Eli Lilly remains larger than Novo Nordisk by market capitalization
“This moment, this insulin moment, this is what really turbocharges them and makes them into one of, if not the first kind of leading American and international pharmaceutical company, which it still is to this day, still bigger than Nova Nordisk. Although not …”
Insulin was the first genetically engineered drug in biotech history
“The first drug that they genetically engineered
And that started this whole revolution was insulin.”
Nordisk licensed NPH insulin globally while refusing to license to Novo
“So Nordisk, rather than building up production facilities around the world, what they decide to do is license it back to basically any interested pharma company. So like Eli Lilly back in the States, other companies in Continental Europe. It's the new, widely …”
Novo Nordisk and Eli Lilly controlled 95% of the insulin market
“So the new combined company has roughly a billion dollars in insulin revenue and 50%, five zero percent global market share with Eli Lilly just behind at 45% and host at five percent.”
Eli Lilly's Byetta became the first GLP-1 drug on market
“Eli Lilly develops it into Bayetta, and Bayetta hits the market in 2005. It's FDA approved, and it works. It's not poisonous. It doesn't kill people. And it is the world's first GLP-I analog to come to market.”
Novo Nordisk, Eli Lilly, and Sanofi control the entire insulin market
“Sanofi today, yeah, the three of those companies are essentially the entire insulin market.”
Eli Lilly traded manufacturing improvements for brand rights in early deal
“The other interesting thing to note about the Eli Lilly license, David, which I thought was really clever, is it's a one-year exclusive license where there's two conditions, and the conditions are a trade. One, Eli Lilly has to report back any advances that th…”
Eli Lilly, Novo, and Nordisk dominated global insulin sales in 1980
“Novo's annual global insulin sales, this is Novo, they're still much larger. They're about a hundred million dollars annually. And Nordisk's are about thirty million annually. That makes them the number two and number four producers in the world by market shar…”
Eli Lilly's tirzepatide secured diabetes approval in 2022 and obesity approval
“It was approved in the US for diabetes treatment in May, 20, 22, and approval just came recently in November, 20, 23 for official FDA sanctioned weight loss use case under the marketing name Zep bound.”